The toxicity of this medication (7-8 times higher than that of procaine), has prevented this medication from being used on its own L1592.
Ester-type local anesthetics are much more likely to cause an allergic reaction compared to the amide-group local anesthetics because of the formation of PABA (Para-aminobenzoic acid) during the metabolic process. PABA may cause allergic reactions that range from urticaria to anaphylaxis. PABA is also formed during the metabolism of methylparaben (a common preservative) that is normally found in multi-dose vials including lidocaine (MDV) (amide-type local anesthetic) L1592, L1593.
Propoxycaine is a local anesthetic of the ester type that has a rapid onset of action and a longer duration of action than procaine hydrochloride L1588. This drug was removed from the US market in 1996. Although no longer available in the United States, this medication was used in combination with procaine to aid in anesthesia during dental procedures L1592. Used in combination with procaine, it was the only dental local anesthetic available in cartridge form L1592.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Hyaluronidase (ovine) | Hyaluronidase (ovine) can cause an increase in the absorption of Propoxycaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Hyaluronidase (human recombinant) | Hyaluronidase (human recombinant) can cause an increase in the absorption of Propoxycaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Hyaluronidase | Hyaluronidase can cause an increase in the absorption of Propoxycaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Technetium Tc-99m tilmanocept | Propoxycaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent. |
| Chloroprocaine | The risk or severity of adverse effects can be increased when Propoxycaine is combined with Chloroprocaine. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Propoxycaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Ropivacaine is combined with Propoxycaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Propoxycaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Cinchocaine is combined with Propoxycaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Dyclonine is combined with Propoxycaine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Procaine is combined with Propoxycaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Prilocaine is combined with Propoxycaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Propoxycaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Meloxicam is combined with Propoxycaine. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Oxybuprocaine is combined with Propoxycaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Cocaine is combined with Propoxycaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Mepivacaine is combined with Propoxycaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Levobupivacaine is combined with Propoxycaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Diphenhydramine is combined with Propoxycaine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Benzocaine is combined with Propoxycaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Phenol is combined with Propoxycaine. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Tetrodotoxin is combined with Propoxycaine. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Benzyl alcohol is combined with Propoxycaine. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Capsaicin is combined with Propoxycaine. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Etidocaine is combined with Propoxycaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Articaine is combined with Propoxycaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Tetracaine is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Propoxycaine is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Propoxycaine is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Propoxycaine is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Propoxycaine is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Propoxycaine is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Propoxycaine is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Propoxycaine is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Propoxycaine is combined with Quinisocaine. |
| Cetuximab | The risk or severity of methemoglobinemia can be increased when Cetuximab is combined with Propoxycaine. |
| Denileukin diftitox | The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Propoxycaine. |
| Leuprolide | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Propoxycaine. |
| Peginterferon alfa-2a | The risk or severity of methemoglobinemia can be increased when Peginterferon alfa-2a is combined with Propoxycaine. |
| Goserelin | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Propoxycaine. |
| Asparaginase Escherichia coli | The risk or severity of methemoglobinemia can be increased when Asparaginase Escherichia coli is combined with Propoxycaine. |
| Interferon alfa-2a | The risk or severity of methemoglobinemia can be increased when Interferon alfa-2a is combined with Propoxycaine. |
| Aldesleukin | The risk or severity of methemoglobinemia can be increased when Aldesleukin is combined with Propoxycaine. |
| Gemtuzumab ozogamicin | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Propoxycaine. |
| Pegaspargase | The risk or severity of methemoglobinemia can be increased when Pegaspargase is combined with Propoxycaine. |
| Trastuzumab | The risk or severity of methemoglobinemia can be increased when Trastuzumab is combined with Propoxycaine. |
| Rituximab | The risk or severity of methemoglobinemia can be increased when Rituximab is combined with Propoxycaine. |
| Tositumomab | The risk or severity of methemoglobinemia can be increased when Tositumomab is combined with Propoxycaine. |
| Alemtuzumab | The risk or severity of methemoglobinemia can be increased when Alemtuzumab is combined with Propoxycaine. |
| Octreotide | The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Propoxycaine. |
| Interferon alfa-2b | The risk or severity of methemoglobinemia can be increased when Interferon alfa-2b is combined with Propoxycaine. |
| Bevacizumab | The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Propoxycaine. |
| Masoprocol | The risk or severity of methemoglobinemia can be increased when Masoprocol is combined with Propoxycaine. |
| Bortezomib | The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Propoxycaine. |
| Pipobroman | The risk or severity of methemoglobinemia can be increased when Pipobroman is combined with Propoxycaine. |
| Cladribine | The risk or severity of methemoglobinemia can be increased when Cladribine is combined with Propoxycaine. |
| Cabergoline | The risk or severity of methemoglobinemia can be increased when Cabergoline is combined with Propoxycaine. |
| Anagrelide | The risk or severity of methemoglobinemia can be increased when Anagrelide is combined with Propoxycaine. |
| Carmustine | The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Propoxycaine. |
| Chlorotrianisene | The risk or severity of methemoglobinemia can be increased when Chlorotrianisene is combined with Propoxycaine. |
| Amsacrine | The risk or severity of methemoglobinemia can be increased when Amsacrine is combined with Propoxycaine. |
| Pamidronic acid | The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Propoxycaine. |
| Bleomycin | The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Propoxycaine. |
| Chlorambucil | The risk or severity of methemoglobinemia can be increased when Chlorambucil is combined with Propoxycaine. |
| Raltitrexed | The risk or severity of methemoglobinemia can be increased when Raltitrexed is combined with Propoxycaine. |
| Mitomycin | The risk or severity of methemoglobinemia can be increased when Mitomycin is combined with Propoxycaine. |
| Bexarotene | The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Propoxycaine. |
| Vindesine | The risk or severity of methemoglobinemia can be increased when Vindesine is combined with Propoxycaine. |
| Valproic acid | The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Propoxycaine. |
| Gefitinib | The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Propoxycaine. |
| Floxuridine | The risk or severity of methemoglobinemia can be increased when Floxuridine is combined with Propoxycaine. |
| Megestrol acetate | The risk or severity of methemoglobinemia can be increased when Megestrol acetate is combined with Propoxycaine. |
| Tioguanine | The risk or severity of methemoglobinemia can be increased when Tioguanine is combined with Propoxycaine. |
| Aminoglutethimide | The risk or severity of methemoglobinemia can be increased when Aminoglutethimide is combined with Propoxycaine. |
| Vinorelbine | The risk or severity of methemoglobinemia can be increased when Vinorelbine is combined with Propoxycaine. |
| Valrubicin | The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Propoxycaine. |
| Sorafenib | The risk or severity of methemoglobinemia can be increased when Sorafenib is combined with Propoxycaine. |
| Streptozocin | The risk or severity of methemoglobinemia can be increased when Streptozocin is combined with Propoxycaine. |
| Trifluridine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Propoxycaine. |
| Gemcitabine | The risk or severity of methemoglobinemia can be increased when Gemcitabine is combined with Propoxycaine. |
| Teniposide | The risk or severity of methemoglobinemia can be increased when Teniposide is combined with Propoxycaine. |
| Epirubicin | The risk or severity of methemoglobinemia can be increased when Epirubicin is combined with Propoxycaine. |
| Lenalidomide | The risk or severity of methemoglobinemia can be increased when Lenalidomide is combined with Propoxycaine. |
| Altretamine | The risk or severity of methemoglobinemia can be increased when Altretamine is combined with Propoxycaine. |
| Flutamide | The risk or severity of methemoglobinemia can be increased when Flutamide is combined with Propoxycaine. |
| Cisplatin | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Propoxycaine. |
| Alitretinoin | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Propoxycaine. |
| Oxaliplatin | The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Propoxycaine. |
| Erlotinib | The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Propoxycaine. |
| Cyclophosphamide | The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Propoxycaine. |
| Toremifene | The risk or severity of methemoglobinemia can be increased when Toremifene is combined with Propoxycaine. |
| Vincristine | The risk or severity of methemoglobinemia can be increased when Vincristine is combined with Propoxycaine. |
| Fluorouracil | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Propoxycaine. |
| Pentostatin | The risk or severity of methemoglobinemia can be increased when Pentostatin is combined with Propoxycaine. |
| Methotrexate | The risk or severity of methemoglobinemia can be increased when Methotrexate is combined with Propoxycaine. |
| Vinblastine | The risk or severity of methemoglobinemia can be increased when Vinblastine is combined with Propoxycaine. |
| Medroxyprogesterone acetate | The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Propoxycaine. |
| Imatinib | The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Propoxycaine. |
| Clofarabine | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Propoxycaine. |
| Prednisone | The risk or severity of methemoglobinemia can be increased when Prednisone is combined with Propoxycaine. |